Journal of Endocrinological Investigation

, Volume 23, Issue 5, pp 310–316 | Cite as

Prevention of early postmenopausal bone loss with cyclical etidronate

  • S. Adami
  • V. Bruni
  • D. Bianchini
  • A. Becorpi
  • P. Lombardi
  • C. Campagnoli
  • A. Ferrari
  • T. Marchesoni
  • R. Balena
Original Article


Cyclical etidronate has been shown to be effective in the treatment of established postmenopausal osteoporosis but less is known about its effects on early menopausal bone loss. The aim of the study was to establish the effects of cyclic etidronate therapy on spinal and proximal femoral bone mineral loss in early post-menopausal women. One hundred and seven women who were within 6 months to 3 years of the menopause were recruited into a 2-year, randomised, placebo-controlled, double-blind trial. Spinal bone mineral density was within 2 SD of the age-matched mean reference value at baseline. Bone mineral density in the lumbar spine and proximal femur was assessed by dual energy X-ray absorptiometry at baseline and thereafter at 6 monthly intervals for 2 years. Urinary collagen cross-links (deoxypyridinoline and pyridinoline) were measured at the same time points. Seventy-seven women completed the study. At the end of the treatment period, the mean bone mineral density change from baseline in the treated group was +0.14% and −0.06% in the lumbar spine and femoral neck, respectively, compared to −1.49 and −2.22 in the control group. Overall, there was a significant difference between the two groups at both these sites (p=0.01 and 0.001, respectively). No significant differences between the groups were demonstrated at the greater trochanter or Ward’s triangle. The conclusion was that cyclical etidronate therapy prevents bone loss in the spine and femoral neck in early postmenopausal women. It provides a safe and effective therapeutic option for the prevention of postmenopausal osteoporosis in women who are unwilling or unable to tolerate hormone replacement therapy.


Cyclical etidronate bisphosphonates early intervention BMD osteoporosis prevention 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lindsay R., Aitken J.M., Anderson J.B. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976, 1 (7968): 1038.PubMedCrossRefGoogle Scholar
  2. 2.
    Hutchinson A., Polansky S.M., Feinstein A.R. Postmenopausal estrogens protect against fractures of the hip and distal radius: a case control study. Lancet 1979, 2: 705.PubMedCrossRefGoogle Scholar
  3. 3.
    Weiss N.S., Ure C.L., Ballard J.H., Williams A.R., Daling J.R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N. Engl. J. Med. 1980, 303: 1195–1198.PubMedCrossRefGoogle Scholar
  4. 4.
    Ettinger B., Genant H.K., Cann C.E. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann. Int. Med. 1985, 102: 319–324.PubMedCrossRefGoogle Scholar
  5. 5.
    Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W.F., Moskowitz M.A. Hip fracture and the use of estrogens in post-menopausal women: the Framingham study. N. Engl. J. Med. 1987, 317: 1169–1174.PubMedCrossRefGoogle Scholar
  6. 6.
    Lufkin E.G., Wahner H.W., O’Fallon W.M., Hodgsons S.F., Kotowicz M.A., Lane A.W., Judd H.L., Caplan R.H., Riggs B.L. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med. 1992, 117: 1–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18: 75–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Storm T., Thamsborg G., Steiniche T., Genant H.K., Sørensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with post-menopausal osteoporosis. N. Engl. J. Med. 1990, 322: 1265–1271.PubMedCrossRefGoogle Scholar
  9. 9.
    Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., Licata A.A., Ross P., Woodson G.C., Yanover M.J., Mysiw W.J., Kohse L., Rao M.B., Steiger P., Richmond B., Chesnut C.H. Intermittent cyclical etidronate treatment of post-menopausal osteoporosis. N. Engl. J. Med. 1990, 323: 72–79.CrossRefGoogle Scholar
  10. 10.
    Storm T., Kollerup G., Thamsborg G., Genant H.K., Sørensen O.H. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J. Rheumatol. 1996, 23: 1560–1564.PubMedGoogle Scholar
  11. 11.
    Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R.J., Kendler D.L., Lentle B., Olszynski W., Ste.-Marie L.G., Tenenhouse A., Chines A.A. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 1997, 337: 382–387.PubMedCrossRefGoogle Scholar
  12. 12.
    Meunier P.J., Confavreux E., Tupinon I., Hardouin C., Delmas P.D., Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J. Clin. Endocrinol. Metab. 1997, 82: 2784–2791.PubMedGoogle Scholar
  13. 13.
    Pouilles J.M., Tremollieres F., Roux C., Sebert J.L., Alexandre C., Goldberg D., Treves R., Khalifa P., Duntze P., Horlait S., Delmas P., Kuntz D. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporos. Int. 1977, 7: 213.CrossRefGoogle Scholar
  14. 14.
    Adami S., Ottanelli S., Lombardi P., Campagnoli C., Ferrari A., Marchesoni D., Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate: a double-blind, placebo-con trolled study. Bone 1998, 23 (5): (Suppl.).Google Scholar
  15. 15.
    Evans R.A., Somers N.M., Dunstan C.R., Royle H., Kos S. The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporos. Int. 1993, 3: 71–75.PubMedCrossRefGoogle Scholar
  16. 16.
    Herd R.J.M., Balena R., Blake G.M., Ryan P.J., Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am. J. Med. 1997, 103: 92–99.PubMedCrossRefGoogle Scholar
  17. 17.
    Peel N.F.A., Eastell R. Comparison of rates of bone loss from the spine measured using two manufacturers’ densitometers. J. Bone Miner. Res. 1995, 10: 1796–1801.PubMedCrossRefGoogle Scholar
  18. 18.
    Grodstein F., Stampfer M.J., Colditz G.A., Willett W.C., Manson J., Joffe M., Rosner B., Fuchs C., Hankinson S.E., Hunter D.J., Hennekens C.H., Speizer F.E. Postmenopausal hormone therapy and mortality. N. Engl. J. Med. 1997, 336: 1769–1775.PubMedCrossRefGoogle Scholar
  19. 19.
    Kawas C., Resnick S., Morrison A., Brookmeyer R., Corrada M., Zonderman A., Bacal C., Longle D.D., Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: The Baltimore Longitudinal Study of Aging. Neurology 1997, 48: 1517–1521.PubMedCrossRefGoogle Scholar
  20. 20.
    Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J., Stampfer M.J., Hennekens C., Rosner B., Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332: 1589–1593.PubMedCrossRefGoogle Scholar
  21. 21.
    Collaborative Group on Hormonal Factors in Breast Cancer: Breast Cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350: 1047–1059.CrossRefGoogle Scholar
  22. 22.
    Compston J.E. Hormone replacement therapy. In: Delmas P.D., Woolf A.D. (Eds.), Osteoporosis. Bailliere’s Clinical Rheumatology, 1997, pp. 583–596.Google Scholar
  23. 23.
    Yates J.A., Roden G.A. Alendronate and osteoporosis. DDT 1998, 3: 69.CrossRefGoogle Scholar
  24. 24.
    Hosking D., Chilvers C., Christiansen C., Ravn P., Wasnich R., Ross P., McClung M., Balske A., Thompson D., Daley M., Yates J.A. Prevention of bone loss with alendronate in post-menopausal women under 60 yeas of age. N. Engl J. Med. 1998, 338: 485.PubMedCrossRefGoogle Scholar
  25. 25.
    De Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J., Pinkas H., Wang K.K. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 1996, 335: 1016–1021.PubMedCrossRefGoogle Scholar
  26. 26.
    Van Staa T. Upper gastrointestinal adverse events and cyclical etidronate. Am. J. Med. 1997, 103: 462.PubMedCrossRefGoogle Scholar
  27. 27.
    Van Staa T.P., Abenhaim L., Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br. J. Rheumatol. 1998, 37: 87–94.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2000

Authors and Affiliations

  • S. Adami
    • 1
  • V. Bruni
    • 2
  • D. Bianchini
    • 1
  • A. Becorpi
    • 2
  • P. Lombardi
    • 6
  • C. Campagnoli
    • 3
  • A. Ferrari
    • 4
  • T. Marchesoni
    • 5
  • R. Balena
    • 7
  1. 1.Centro Ospedaliero Clinicizzato di ValeggioUniversity of VeronaValeggio, VeronaItaly
  2. 2.University of FlorenceItaly
  3. 3.University of TurinItaly
  4. 4.University of MilanItaly
  5. 5.University of PaduaItaly
  6. 6.Istituti Ospedalieri of BergamoItaly
  7. 7.Procter and Gamble Pharmaceuticals StainesUK

Personalised recommendations